August 2022
Starting from:
£99 + VAT
Format: DOWNLOADABLE PDF
This conference focused on the future for life sciences in the UK.
It was an opportunity to assess changes to regulation and evaluation - and the support, frameworks, partnerships and investment required for the life sciences industry to navigate the way forward.
Areas for discussion included the use of data and real-world evidence, efficiencies within clinical trials, and taking a mission-led approach to healthcare challenges.
Delegates also examined priorities for sector investment, funding and growth, with the new Life Sciences Innovative Manufacturing Fund, and in the context of:
- the Innovative Medicines Fund
- the plans for the sector set out by the Government in the Life Sciences Vision
- the industry moving forward on the back of developments during the COVID-19 pandemic
Areas for discussion included:
- Life Sciences Vision - implementation of strategic ambitions - priorities for channelling investment
- mission-led approach - stakeholder collaboration - targeting investment and funding - learning from the development of the COVID-19 vaccine
- sector growth - support for innovation and manufacturing - government funding - developing the business environment to support growth and healthcare ambitions - global competitiveness
- new approaches to evaluation - effective stakeholder use of regulatory flexibility - frameworks for data use to support new methods
- clinical trials - opportunities to address bureaucracy - improving efficiency and participation - accessing harder-to-reach population groups
- data and real-world evidence - clarity on what is needed for the sector to capitalise on potential
- personalised, predictive and preventive healthcare - next steps - patient access - commercialisation - tackling inequality in health outcomes
We are very pleased to have been able to include keynote sessions with Rosalind Campion, Director, Office for Life Sciences; Dr Jennifer Harris, Director of Research Policy, ABPI; and Shuna Mason, Partner, CMS UK Lifesciences Division.
The discussion brought together stakeholders with key policy officials who attended from the OLS; DHSC; MHRA; Department of Health, NI; GO-Science; HM Treasury; House of Commons Library; NIHR and The Scottish Government.
